Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Dec 05, 2020 12:24pm
108 Views
Post# 32043981

RE:RE:RE:RE:Any idea why the new warrants are priced

RE:RE:RE:RE:Any idea why the new warrants are priced Those aren't the same warrants, those are warrants used to pay for services and aren't bought or sold on the open market. The warrant revaluation you see in our quarterlies is simply a caluclation of the outstanding warrants that haven't been exercised used to pay for services, specifically to LIND, and it's because as long as they aren't exercised the debt is technically not paid and will count as a debt on our balance sheets. Again it's lame but we're stuck with it.  The WT and WS warrant prices are decided by you, me and the open market.


brad129 wrote:

lithlover posted a good post on the warrant side of things, we've seen them in the quarterly reports being re-evaluated my question is they can re-evaluate them lower but if the share price rises do they re-evaluate them up?


 

InvrsContrarian wrote: Ok corrected here for the ws warrants. Each Warrant is exercisable to purchase one Common Share at any time prior to December 4, 2023 at a price of $1.10 per Common Share. There's your answer as to why the warrants are price higher. In actual fact: at wt.0.07x8=0.56+0.72=1.28 Ws. 0.18+1.10=1.28 So someone got a bargain first thing this morning when they sold for 0.16

 

 



<< Previous
Bullboard Posts
Next >>